These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28671136)

  • 21. Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.
    McGarry A; Auinger P; Kieburtz K; Geva M; Mehra M; Abler V; Grachev ID; Gordon MF; Savola JM; Gandhi S; Papapetropoulos S; Hayden M
    J Huntingtons Dis; 2020; 9(2):173-184. PubMed ID: 32508327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive assessment in Huntington disease clinical drug trials.
    Stout JC; Andrews SC; Glikmann-Johnston Y
    Handb Clin Neurol; 2017; 144():227-244. PubMed ID: 28947120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.
    Smith KM; Matson S; Matson WR; Cormier K; Del Signore SJ; Hagerty SW; Stack EC; Ryu H; Ferrante RJ
    Biochim Biophys Acta; 2006 Jun; 1762(6):616-26. PubMed ID: 16647250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
    Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.
    ; Hyson HC; Kieburtz K; Shoulson I; McDermott M; Ravina B; de Blieck EA; Cudkowicz ME; Ferrante RJ; Como P; Frank S; Zimmerman C; Cudkowicz ME; Ferrante K; Newhall K; Jennings D; Kelsey T; Walker F; Hunt V; Daigneault S; Goldstein M; Weber J; Watts A; Beal MF; Browne SE; Metakis LJ
    Mov Disord; 2010 Sep; 25(12):1924-8. PubMed ID: 20669312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A futility study of minocycline in Huntington's disease.
    Huntington Study Group DOMINO Investigators
    Mov Disord; 2010 Oct; 25(13):2219-24. PubMed ID: 20721920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study of virtual visits in Huntington disease.
    Bull MT; Darwin K; Venkataraman V; Wagner J; Beck CA; Dorsey ER; Biglan KM
    J Huntingtons Dis; 2014; 3(2):189-95. PubMed ID: 25062861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The CREST-E study of creatine for Huntington disease: A randomized controlled trial.
    Hersch SM; Schifitto G; Oakes D; Bredlau AL; Meyers CM; Nahin R; Rosas HD;
    Neurology; 2017 Aug; 89(6):594-601. PubMed ID: 28701493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.
    Squitieri F; Di Pardo A; Favellato M; Amico E; Maglione V; Frati L
    J Cell Mol Med; 2015 Nov; 19(11):2540-8. PubMed ID: 26094900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.
    Chen M; Ona VO; Li M; Ferrante RJ; Fink KB; Zhu S; Bian J; Guo L; Farrell LA; Hersch SM; Hobbs W; Vonsattel JP; Cha JH; Friedlander RM
    Nat Med; 2000 Jul; 6(7):797-801. PubMed ID: 10888929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.
    López-Sendón Moreno JL; García Caldentey J; Trigo Cubillo P; Ruiz Romero C; García Ribas G; Alonso Arias MA; García de Yébenes MJ; Tolón RM; Galve-Roperh I; Sagredo O; Valdeolivas S; Resel E; Ortega-Gutierrez S; García-Bermejo ML; Fernández Ruiz J; Guzmán M; García de Yébenes Prous J
    J Neurol; 2016 Jul; 263(7):1390-400. PubMed ID: 27159993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minocycline in Huntington's disease: a pilot study.
    Thomas M; Ashizawa T; Jankovic J
    Mov Disord; 2004 Jun; 19(6):692-5. PubMed ID: 15197710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparing for preventive clinical trials: the Predict-HD study.
    Paulsen JS; Hayden M; Stout JC; Langbehn DR; Aylward E; Ross CA; Guttman M; Nance M; Kieburtz K; Oakes D; Shoulson I; Kayson E; Johnson S; Penziner E;
    Arch Neurol; 2006 Jun; 63(6):883-90. PubMed ID: 16769871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.
    Naia L; Ribeiro MJ; Rego AC
    Rev Neurosci; 2011 Dec; 23(1):13-28. PubMed ID: 22150069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between CAG repeat length and clinical progression in Huntington's disease.
    Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP
    Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature.
    Mason SL; Barker RA
    Expert Opin Pharmacother; 2016; 17(1):41-52. PubMed ID: 26536068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monozygotic twins suffering from Huntington's disease show different cognitive and behavioural symptoms.
    Gómez-Esteban JC; Lezcano E; Zarranz JJ; Velasco F; Garamendi I; Pérez T; Tijero B
    Eur Neurol; 2007; 57(1):26-30. PubMed ID: 17108691
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.